7 October 2024 - Neuvivo today announced it submitted a new drug application to the US FDA for NP001 (sodium chlorite infusion) to treat amyotrophic lateral sclerosis. 

NP001 is an investigational treatment that, if approved, could be the first disease-modifying therapy for amyotrophic lateral sclerosis that restores balance over uncontrolled inflammation within the body’s own innate immune system.

Read Neuvivo press release